Who is sponsoring NCT02884648?

NCT02884648 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT02884648?

Interventions in NCT02884648: Bevacizumab.

What condition does NCT02884648 study?

NCT02884648 studies Malignant Neoplasms of Female Genital Organs, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer.

Is NCT02884648 still recruiting?

NCT02884648 is currently active, enrolled. Last updated 6 February 2026.

Last reviewed 2026-02-06 · How we verify

NCT02884648

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery

Active, enrolled Phase 2 Last updated 6 February 2026

What this trial tests

Phase 2 trial testing Bevacizumab in Malignant Neoplasms of Female Genital Organs in 35 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

15 November 2016

Primary endpoint
2 February 2027

2 February 2027

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	35
Start date	15 November 2016
Primary completion	2 February 2027
Estimated completion	2 February 2027
Sites	1 location across United States

Drugs / interventions tested

Bevacizumab (Bevacizumab-Bvzr) — full drug profile →

Conditions studied

Malignant Neoplasms of Female Genital Organs — all drugs for Malignant Neoplasms of Female Genital Organs →
Ovarian Cancer — all drugs for Ovarian Cancer →
Fallopian Tube Cancer — all drugs for Fallopian Tube Cancer →
Primary Peritoneal Cancer — all drugs for Primary Peritoneal Cancer →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, female only, with Malignant Neoplasms of Female Genital Organs or Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this clinical research study is to learn if Avastin (bevacizumab) can help to control ovarian, fallopian, or primary peritoneal cancer that has been found during second-look surgery.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Bevacizumab

Trials testing the same drug.

NCT07504588 — Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and · Phase 2 · not yet recruiting
NCT07500298 — Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable · Phase 1 · not yet recruiting
NCT07271355 — Pressurized Intraperitoneal Aerosolized Chemotherapy With Mitomycin for the Treatment of Unresectable Appendix or Colore · Phase 3 · not yet recruiting
NCT07318389 — ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer · EARLY_PHASE1 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting

Other recruiting trials for Malignant Neoplasms of Female Genital Organs

Currently open trials in the same condition.

NCT03531645 — Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma · Phase 2 · active not recruiting
NCT03435952 — Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NT · Phase 1 · active not recruiting
NCT03093909 — Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases · Phase 1 · recruiting
NCT03162627 — Selumetinib and Olaparib in Solid Tumors · Phase 1 · active not recruiting
NCT02774759 — Feasibility of the NEXT Steps Weight Loss Intervention +/- Resistance Training for Endometrial Cancer Survivors: Effect · NA · active not recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02884648 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 6 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02884648.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing